Basic research of adjuvant chemotherapy for locally invasive bladder cancer

局部浸润性膀胱癌辅助化疗的基础研究

• 批准号: 04670976
• 负责人: OKAJIMA Eigoro
• 金额: $ 1.28万
• 依托单位: Nara Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1992
• 资助国家: 日本
• 起止时间: 1992 至 1994
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-04670976/
• 关键词: invasive bladder cancer; chemical carcinogenesis; N-butyl-N- (4-hydroxybutyl) nitrosamine (BBN); chemotherapy; mouse; 湿潤性膀胱がん; N-butyl-N-(4-hydroxybutyl) nitrosamine(BBN); 化学発癌; N-butyl-N-(4-hydroxybutyl)nitrosamine(BBN)

The present investigation was conducted to establish clinically useful multidisciplinary treatment for invasive bladder cancer. Since 1992, we examined the effects of combination chemotherapeutic regiments, CPM+THP-ADM+CDDP (CAP), MTX+VLB+THP-ADM+CDDP (M-VAC) and MTX+Epi-ADM+CDDP (MEC) on the urinary bladder carcinogenesis induced by N-butyl-N- (4-hydroxybutyl) nitrosamine (BBN) in mice. Those experiments include two objectives to examine ; 1) the effects on the development of bladder carcinoma (Exp.1), and 2) the effects on the bladder carcinoma, anti-tumor effects (Exp.2). In Exp.1, animals received 3 cycles of CAP every 3 weeks or 3 cycles of M-VAC or MEC every 4 weeks after 0.05% BBN treatment for 12 weeks. On the other hand, In Exp.2, animals received each regimen with same manner as Exp.1 after 0.5% BBN treatment for 12 weeks and no treatment for 16 weeks. In Exp.1, tumor incidences of chemotherapy groups were significantly lower than that of BBN alone group. However, in Exp.2, significant difference was not observed between every two groups. Therefore, inhibitory effects of CAP,M-VAC and MEC on the development of mouse bladder carcinoma were seen. These results suggested that CAP,M-VAC and MEC were useful regimens for adjuvant chemotherapy for invasive bladder cancer.

本研究旨在建立临床上有用的浸润性膀胱癌多学科治疗方法。自1992年以来，我们研究了CPM+THP-ADM+CDDP（CAP）、MTX+VLB+THP-ADM +CDDP（M-VAC）和MTX+Epi-ADM+CDDP（MEC）联合化疗方案对N-丁基-N-（4-羟丁基）亚硝胺（BBN）诱发小鼠膀胱癌的影响。这些实验包括两个目的来检查：1）对膀胱癌发展的作用（实验1），和2）对膀胱癌的作用，抗肿瘤作用（实验2）。在实验1中，在0.05% BBN处理12周后，动物每3周接受3个周期的CAP或每4周接受3个周期的M-VAC或MEC。另一方面，在实验2中，动物在0.5%BBN处理12周和不处理16周后以与实验1相同的方式接受每种方案。在实验1中，化疗组的肿瘤发生率显著低于单独BBN组。然而，在实验2中，每两组之间未观察到显著差异。因此，CAP、M-VAC和MEC对小鼠膀胱癌的发展具有抑制作用。提示CAP、M-VAC和MEC是浸润性膀胱癌辅助化疗的有效方案。

项目成果

松木 尚・他: "尿路性器悪性腫瘍におけるcirculating immune complexesの検討" 奈医誌. 43. 34-40 (1992)

Nao Matsuki 等人：“泌尿道恶性肿瘤中循环免疫复合物的检查”Nai-ishi，43. 34-40 (1992)。

平尾佳彦・他: "尿路性器癌培養細胞の細胞増殖におよぼすRhodamine 123の影響" 泌尿紀要. 39. 1233-1240 (1993)

Yoshihiko Hirao 等人：“罗丹明 123 对培养的泌尿生殖癌细胞增殖的影响”Urinary Bulletin 39. 1233-1240 (1993)。

大園誠一郎: "モダン・クリニカルポイント 泌尿器科:浸潤性膀胱癌に対するminimally invasive surgery." 金原出版, 2 (1993)

Seiichiro Ozono：“现代临床要点泌尿外科：浸润性膀胱癌的微创手术”，Kanehara Publishing，2 (1993)。

Hayashi,Y.,et al.: "Effect of combination chemotherapy including cyclophosphamide,THP-adriamycin,and cisplatin on the development of urinary bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats." J.Toxicol. Pathol.5(1). 61-66 (1992)

Hayashi,Y.,et al.：“环磷酰胺、THP-阿霉素和顺铂联合化疗对 N-丁基-N-(4-羟丁基)亚硝胺诱导的大鼠膀胱癌发生的影响”。

岡島英五郎・他: "抗癌剤感受性試験の現況と将来展望" 医学のあゆみ. 165(12). 864-866 (1993)

Eigoro Okajima 等人：“抗癌药物敏感性测试的现状和未来前景”，History of Medicine 165(12) (1993)。